Fernandez-Retana Jorge, Zamudio-Meza Horacio, Rodriguez-Morales Miguel, Pedroza-Torres Abraham, Isla-Ortiz David, Herrera Luis, Jacobo-Herrera Nadia, Peralta-Zaragoza Oscar, López-Camarillo César, Morales-Gonzalez Fermin, Cantu de Leon David, Pérez-Plasencia Carlos
1 FES Iztacala, UBIMED, UNAM, Tlalnepantla, Mexico.
2 Genomics Laboratory, National Cancer Institute, Mexico City, Mexico.
Tumour Biol. 2017 Jun;39(6):1010428317711895. doi: 10.1177/1010428317711895.
Cervical cancer is one of the leading causes of death in women worldwide, which mainly affects developing countries. The patients who suffer a recurrence and/or progression disease have a higher risk of developing distal metastases. Proteases comprising the degradome given its ability to promote cell growth, migration, and invasion of tissues play an important role during tumor development and progression. In this study, we used high-density microarrays and quantitative reverse transcriptase polymerase chain reaction to evaluate the degradome profile and their inhibitors in 112 samples of patients diagnosed with locally advanced cervical cancer. Clinical follow-up was done during a period of 3 years. Using a correlation analysis between the response to treatment and the development of metastasis, we established a molecular signature comprising eight degradome-related genes (FAM111B, FAM111A, CFB, PSMB8, PSMB9, CASP7, PRSS16, and CD74) with the ability to discriminate patients at risk of distal metastases. In conclusion, present results show that molecular signature obtained from degradome genes can predict the possibility of metastasis in patients with locally advanced cervical cancer.
宫颈癌是全球女性主要死因之一，主要影响发展中国家。患有复发性和/或进展性疾病的患者发生远处转移的风险更高。蛋白酶组成的降解组因其促进细胞生长、迁移和组织侵袭的能力，在肿瘤发生和进展过程中发挥重要作用。在本研究中，我们使用高密度微阵列和定量逆转录聚合酶链反应来评估112例诊断为局部晚期宫颈癌患者样本中的降解组谱及其抑制剂。临床随访为期3年。通过治疗反应与转移发生之间的相关性分析，我们建立了一个由八个降解组相关基因（FAM111B、FAM111A、CFB、PSMB8、PSMB9、CASP7、PRSS16和CD74）组成的分子特征，该特征能够区分有远处转移风险的患者。总之，目前的结果表明，从降解组基因获得的分子特征可以预测局部晚期宫颈癌患者发生转移的可能性。
